Simmitinib plus irinotecan for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new combination of two drugs—simmitinib (a targeted therapy) and irinotecan (a chemotherapy)—for people with advanced esophageal cancer that has stopped responding to one prior treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced esophageal squamous cell carcinoma that has worsened after one prior standard treatment (like chemotherapy plus an immunotherapy).
- You are between 18 and 70 years old.
- You have at least one measurable tumor (visible on a scan).
- You are generally able to take care of yourself (ECOG score 0-1).
- Your blood counts, liver, and kidney function are within certain limits (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (anlotinib and benmelstobart) as a first treatment for people with advanced esophageal squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if this combination helps control the cancer.
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
This trial tests a new drug called simmitinib against standard chemotherapy for people with advanced esophageal squamous cell carcinoma that has progressed after one prior treatment. The goal is to see if simmitinib works better than chemo.
This trial tests adding liposomal irinotecan to standard chemotherapy and radiation for locally advanced esophageal squamous cell cancer. The goal is to see if this combination works better than current treatments.
This trial tests a combination of two chemotherapy drugs (liposomal irinotecan and 5-FU) for people whose esophageal cancer didn't respond to or couldn't tolerate the first treatment. The goal is to see if this second-line therapy can shrink tumors or slow their growth.
This trial tests a combination of an immunotherapy drug (sintilimab) plus chemotherapy followed by radiation therapy for advanced esophageal cancer that has spread. The goal is to see if this sequence can help shrink tumors and improve outcomes.
Hear when a new Advanced Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.